艾迪持续动脉灌注联合栓塞治疗伴有肝细胞黄疸的肝脏恶性肿瘤

目的观察艾迪持续动脉灌注联合栓塞治疗伴有肝细胞黄疸的肝脏恶性肿瘤的临床疗效。方法对49例伴有肝细胞黄疸的原发肝癌和肝转移癌患者经左锁骨下动脉留置导管内灌注艾迪注射液并进行栓塞治疗。结果49例患者中,有1例死亡;2例中途放弃治疗,共46例完成治疗。0.5、1、2、3年生存率为89.1%（41/46）,34.8%（16/46）,17.4%（8/46）,4.3%（2/46）。结论对于伴有肝细胞黄疸的原发肝癌和肝转移癌患者,使用艾迪持续动脉灌注联合栓塞可以在改善肝功能的前提下,有效的控制肿瘤,同时提高患者的免疫功能和生存率。     

手术前动脉介入化疗对胃癌患者外周血淋巴细胞化学发光的影响

目的 :研究手术前动脉介入化疗对胃癌患者外周血淋巴细胞化学发光的影响。　方法 :选择 70例胃癌患者 ,分别在术前动脉介入化疗前和化疗后 1、3、5、7天抽取患者外周静脉血 ,分离淋巴细胞进行化学发光 (Ly CL)和细胞周期动力学检测 ,观察其化疗前、后的变化。　结果 :胃癌患者化疗后 2 4hLy CL迅速降低 (P <0 .0 1) ,最低值一般出现在化疗后 3～ 5天 ,然后逐渐上升 ,第 7天时基本恢复至化疗前的水平 (P >0 .0 5 )。同时淋巴细胞增生指数也有相同的变化 ,与Ly CL呈明显的正相关 (r =0 .6 1,P <0 .0 1)。　结论 :测定Ly CL强度变化可反映胃癌患者在术前动脉介入化疗过程中淋巴细胞免疫功能的变化 ,可作为患者免疫功能改变的动态观察指标 ,指导诊断和治疗。     

微波辅助介入治疗肝癌43例

目的 观察肝癌患者动脉灌注与栓塞配合热疗的治疗效果。方法 1999/2003对43例肝癌患者进行动脉超选灌注加热至43℃的顺铂80mg+阿毒素20mg,然后经导管灌注混有阿霉素20mg+丝裂霉素20mg的超液态碘油乳化剂进行栓塞,术中和术后4d,8d,12d,16d运用WF-2102A微波热疗治疗仪进行配合治疗,每次40min,电脑显示测温要求在43℃。结果半年生存率(39/43)90％,la生存率(27/23)62.7％,2a生存率(9/43)20.9％,3a生存率(6/43)13.9％。结论肝癌动脉灌注与栓塞配合热疗临床观察表明,该方法疗效显著,应成为一项重要的非手术治疗方案。     

Role of Subordination in Nephritis of Socially Stressed Mice

A behavioral etiology of interstitial nephritis of male CBA mice chronically exposed to psychosocial stress is suspected. The blood urea nitrogen of these animals is inversely proportional to social status as measured by behavior and the appearance of fur. Blood pressure measurement tends toward an opposite relationship. Since subordinates have difficulty urinating in the presence of dominants and suffer from overfilled bladders, their fatal tubulointerstitial involvement may originate with repeated episodes of urinary reflux.     

支气管动脉内灌注化疗药物并发脊髓损伤的初步探讨

作者对３７例肺癌患者进行了１２５次支气管动脉造影和动脉内灌注化疗药物（顺铂、丝裂霉素、５－氟脲嘧啶），其中１例在灌注的同时加用５ｍｌ碘苯酯经乳化后进行支气管动脉栓塞。共发生３例脊髓损伤，１例在支气管动脉栓塞后即出现截瘫，另两例为术后第３～４ｄ出现右下肢麻木无力及小便困难，继而出现两下肢瘫痪及大小便失禁。症状出现后用激素、神经营养药及对症处理后均有好转。作者对并发脊髓损伤的原因、预防措施及治疗作了初步探讨。     

选择性支气管动脉插管药物治疗中,晚期肺癌

对34例中晚期肺癌进行选择性支气管动脉插管药物灌注.药物为 LAK 细胞,IL-2、卡铂、表阿霉素。结果显示,肿块明显消退12例占35.2%,部分消退18例占52.5%、无变化4例占12.7%、总有效率为87.3%。通过对支气管动脉插管技术,灌注疗法同其它治疗方法的优缺点进行比较,认为本疗法优于周围静脉给药且无严重并发症,副作用轻,不失为一种可供选择的治疗方法.     

术前区域动脉持续灌注化疗并栓塞治疗局部晚期乳腺癌的临床观察

目的：观察术前区域动脉持续灌注化疗并栓塞治疗局部晚期乳腺癌的效果。方法：应用术前超选择区域动脉插管持续灌注化疗结合次要供血动脉栓塞的方案,经治Ⅲａ,ｂ 期乳腺癌患者９ 例。结果：在治疗后的１ 个月内取得良好效果,有效率达８９ ％ （８／９） 。结论：局部晚期乳腺癌术前区域动脉持续灌注化疗配合次要供血动脉栓塞可有效提高术前化疗疗效,显著缩短疗程且毒副反应小、简便,值得推广应用。     

区域动脉灌注治疗重症急性胰腺炎116例报告

目的为探讨提高重症急性胰腺炎的疗效。方法应用Ｓｅｌｄｉｎｇｅｒ法,置导管于胰腺病变供血动脉内,灌注抑酶制剂和抗生素,以提高进入胰腺组织内的药物浓度,达到控制胰腺病变和预防继发性感染的目的。结果通过１１６例区域动脉灌注的方法和综合疗法,明显减少了坏死胰腺组织的感染,降低了死亡率。结论该法是治疗重症急性胰腺炎的新疗法,特别适合于胰腺早期病变的治疗。     

Laparoscopic Placement of Hepatic Artery Infusion Pumps: Technical Considerations and Early Results

Background Laparoscopic hepatic artery infusion pump (LHAIP) placement is a novel treatment option for patients with colorectal liver metastases. This study investigates technical difficulties with regard to variant hepatic arteries and the preliminary outcomes for patients treated with LHAIP placement.Methods Between March 1998 and January 2003, 38 patients with colorectal metastases confined to the liver, 35 (92%) of who had prior systemic chemotherapy that failed, were treated with LHAIP.Results Twelve patients (32%) had LHAIP placement only, and 26 (68%) had pump placement combined with laparoscopic radiofrequency ablation (LRFA; 24 patients) and/or liver resection (2 patients). Variant hepatic arterial (HA) anatomy was present in 18 patients (47%). The presence of a variant HA did not increase pump complications, operative time, or blood loss (P .20) or decrease the functional time of pump use (P = .91) in comparison with normal anatomy. In all patients with a variant HA, laparoscopic ligation of the variant vessel and/or cannulation of nongastroduodenal artery resulted in complete hepatic perfusion. Three misperfusions identified intraoperatively with use of methylene blue injection were corrected by laparoscopic ligation (two) or postoperative angioembolization (one). Postoperative pump radionuclide flow studies confirmed isolated hepatic artery infusion in all cases. There was a 13% pump-related complication rate. During a median follow-up of 11 months (0.5 to 35.5 months), the actuarial rate of overall survival was 47% and the estimated median survival time was 17.5 months.Conclusions LHAIP placement is technically feasible, and variant HA is not associated with increased pump complications or decreased pump functional time.